KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Raw Materials: 2010-2012

Historic Raw Materials for Jazz Pharmaceuticals (JAZZ) over the last 1 years, with Sep 2012 value amounting to $5.9 million.

  • Jazz Pharmaceuticals' Raw Materials was N/A to $5.9 million in Q3 2012 from the same period last year, while for Sep 2012 it was $5.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2011, which is 35.13% down from last year.
  • As of Q3 2012, Jazz Pharmaceuticals' Raw Materials stood at $5.9 million, which was up 43.54% from $4.1 million recorded in Q2 2012.
  • Over the past 5 years, Jazz Pharmaceuticals' Raw Materials peaked at $5.9 million during Q3 2012, and registered a low of $1.9 million during Q4 2011.
  • Moreover, its 3-year median value for Raw Materials was $3.1 million (2012), whereas its average is $3.6 million.
  • Data for Jazz Pharmaceuticals' Raw Materials shows a maximum YoY plummeted of 35.13% (in 2011) over the last 5 years.
  • Jazz Pharmaceuticals' Raw Materials (Quarterly) stood at $3.0 million in 2010, then crashed by 35.13% to $1.9 million in 2011, then reached $5.9 million in 2012.
  • Its last three reported values are $5.9 million in Q3 2012, $4.1 million for Q2 2012, and $3.1 million during Q1 2012.